Recce Pharmaceuticals

Corporate Governance

Why Invest

News and Media

Announcements

Titillium Web

Recce's Entitlement Offer is now live! Visit the page for instructions on how to participate

Recce Pharmaceuticals’ (ASX:RCE) R327 demonstrates notable bacterial reduction activity against the life-threatening STD, N. gonorrhoeae

A study was conducted by the Murdoch Children’s Research Institute to test the efficacy of R327 on mouse vaginal infection models

Mice were inoculated vaginally with N. gonorrhoea and after receiving R327 over three days at an IV dose of 1000mg/kg bacterial shedding was significant

N. gonorrhoea is listed on the WHO’s priority pathogen list of bacteria posing the greatest threat to human health, and many antibiotics are now resistant to it

Recce Pharmaceuticals’ (ASX:RCE) lead anti-infective drug, R327 has shown significant bacterial reduction against the life-threatening sexually transmitted disease (STD), Neisseria gonorrhoeae (N. gonorrhea).

A study by the Murdoch Children’s Research Institute tested R327’s efficacy on a mouse vaginal infection model. Ten mice were inoculated vaginally with N. gonorrhoeae.

Administered twice daily through an intravenous bolus dose of 1000 milligrams per kilogram (mg/kg), R327 achieved a 99.99 per cent reduction in bacterial shedding within just three days.

N. gonorrhoeae is a top-priority pathogen on the World Health Organisation’s list due to the increasing prevalence of antibiotic-resistant strains and its potential for severe health consequences.

“The need for a new class of anti-infectives could not be greater, especially against a lethal pathogen such as N. gonorrhoea,” RCE CEO James Graham said.

“The data from this study, along with the previous findings, emphasise the capability of R327 to demonstrate broad spectrum activity against antibiotic-resistant bacteria, even with repeated use.”

Read the full article here: https://themarketherald.com.au/recce-pharmaceuticals-lead-anti-infective-r327-shows-promise-against-deadly-std-in-latest-animal-study-2023-12-14/

Recce Pharmaceuticals lead anti-infective R327 shows promise against deadly STD in latest animal study